SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus Remedies informs about press release

01 Dec 2023 Evaluate
Venus Remedies has informed that it has received Marketing Authorizations for Paclitaxel 100m9/16.7rn1 and Zolendronic Acid 4mg in the Philippines, located in the dynamic region of Asia (South East). ln addition, the company has also secured Marketing Authorization for Bleomycin 1SlU from SaudiArabia. These regulatory approvals signify a significant milestone for Venus Remedies, reflecting the company's commitment to advancing healthcare solutions and expanding its global presence. The company is dedicated to delivering high-quality pharmaceuticals that contribute to improving patient outcomes and addressing critical medical needs. Press release of the same is enclosed.

The above information is a part of company’s filings submitted to BSE.

Venus Remedies Share Price

1735.30 70.65 (4.24%)
07-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1903.00
Dr. Reddys Labs. 1353.75
Cipla 1452.35
Zydus Lifesciences 1152.90
Lupin 2489.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: